Literature summary for 3.4.21.B2 extracted from

Schiffer, S.; Letzian, S.; Jost, E.; Mladenov, R.; Hristodorov, D.; Huhn, M.; Fischer, R.; Barth, S.; Thepen, T.
Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells (2013), Cancer Lett., 341, 178-185.

Search for more literature for 3.4.21.B2

Application

Application	Comment	Organism
medicine	use of granzyme M as an alternative component of human cytolytic fusion proteins. Upon fusion to the humanized single-chain antibody fragment (scFv) H22 which specifically binds to CD64, an FccRI receptor overexpressed on activated myeloid cells and leukemic cells, the humanized cytolytic fusion protein specifically targets the acute myeloid leukemia cell line HL60 in vitro and is cytotoxic with an IC50 between 1.2 and 6.4 nM. These findings are confirmed ex vivo using leukemic primary cells from patients, which are killed by granzyme M despite the presence of the granzyme B inhibitor serpin B9	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	P51124	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)